File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain

TitleDose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain
Authors
KeywordsAged
Antibody titer
Arthralgia
Drug dosage form comparison
Drug dose comparison
Issue Date2012
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2012, v. 30 n. 45, p. 6427-6435 How to Cite?
AbstractBACKGROUND: We hypothesized that low dose intradermal vaccination of the trivalent influenza vaccine (TIV) delivered by the MicronJet600 (NanoPass Technologies, Israel) would be non-inferior to the full dose intramuscular and mid dose Intanza((R)) vaccination in the elderly and the chronically ill adults. METHODS: We performed a prospective randomized trial on elderly and chronically ill adults. Subjects were randomly assigned into 4 groups. Groups ID3 and ID9 received reduced dose ID TIV (3 mug and 9 mug of hemagglutinin (HA) per strain respectively) delivered by MicronJet600 (NanoPass Technologies, Israel). Group INT9 received reduced dose ID TIV (9 mug) delivered by Becton Dickinson's Soluvia device (Intanza((R))9, Sanofi-Pasteur, France). Control group IM15 received a full dose IM TIV (15 mug). We measured antibody titers by hemagglutination inhibition (HAI) and microneutralization (MN) assays at baseline and day 21. RESULTS: Baseline characteristics for all groups were similar (group and sample sizes: ID3=63; ID9=68; INT9=65; and IM15=66). At day 21 post vaccination, the GMT ratio and the seroconversion rates difference for all three strains of the ID vaccine groups were non-inferior to the IM vaccine group. The seroconversion rate, seroprotection rate, and the GMT of the H1N1 strains by HAI and MN assays were significantly higher in the ID groups compared with the full dose IM vaccine group. The seroconversion rates of the H3N2 strain by HAI assay were also significantly higher in the ID groups when compared with the full dose IM group. Direct comparison among the three ID groups showed no significant differences. No serious adverse events related to vaccination were reported. CONCLUSION: Dose-sparing ID TIV can overcome reduced immunogenicity of the H1N1 strain, and according to some measures, for the H3N2 strain. At risk subjects indicated for the TIV should be considered for intradermal immunization to compensate for reduced immunogenicity.
Persistent Identifierhttp://hdl.handle.net/10722/164354
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHung, IFNen_US
dc.contributor.authorLevin, Yen_US
dc.contributor.authorTo, KKWen_US
dc.contributor.authorChan, KHen_US
dc.contributor.authorZhang, AJ-
dc.contributor.authorLi, P-
dc.contributor.authorLi, C-
dc.contributor.authorXu, T-
dc.contributor.authorWong, TY-
dc.contributor.authorYuen, KY-
dc.date.accessioned2012-09-20T07:58:09Z-
dc.date.available2012-09-20T07:58:09Z-
dc.date.issued2012en_US
dc.identifier.citationVaccine, 2012, v. 30 n. 45, p. 6427-6435en_US
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/164354-
dc.description.abstractBACKGROUND: We hypothesized that low dose intradermal vaccination of the trivalent influenza vaccine (TIV) delivered by the MicronJet600 (NanoPass Technologies, Israel) would be non-inferior to the full dose intramuscular and mid dose Intanza((R)) vaccination in the elderly and the chronically ill adults. METHODS: We performed a prospective randomized trial on elderly and chronically ill adults. Subjects were randomly assigned into 4 groups. Groups ID3 and ID9 received reduced dose ID TIV (3 mug and 9 mug of hemagglutinin (HA) per strain respectively) delivered by MicronJet600 (NanoPass Technologies, Israel). Group INT9 received reduced dose ID TIV (9 mug) delivered by Becton Dickinson's Soluvia device (Intanza((R))9, Sanofi-Pasteur, France). Control group IM15 received a full dose IM TIV (15 mug). We measured antibody titers by hemagglutination inhibition (HAI) and microneutralization (MN) assays at baseline and day 21. RESULTS: Baseline characteristics for all groups were similar (group and sample sizes: ID3=63; ID9=68; INT9=65; and IM15=66). At day 21 post vaccination, the GMT ratio and the seroconversion rates difference for all three strains of the ID vaccine groups were non-inferior to the IM vaccine group. The seroconversion rate, seroprotection rate, and the GMT of the H1N1 strains by HAI and MN assays were significantly higher in the ID groups compared with the full dose IM vaccine group. The seroconversion rates of the H3N2 strain by HAI assay were also significantly higher in the ID groups when compared with the full dose IM group. Direct comparison among the three ID groups showed no significant differences. No serious adverse events related to vaccination were reported. CONCLUSION: Dose-sparing ID TIV can overcome reduced immunogenicity of the H1N1 strain, and according to some measures, for the H3N2 strain. At risk subjects indicated for the TIV should be considered for intradermal immunization to compensate for reduced immunogenicity.-
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine-
dc.relation.ispartofVaccineen_US
dc.subjectAged-
dc.subjectAntibody titer-
dc.subjectArthralgia-
dc.subjectDrug dosage form comparison-
dc.subjectDrug dose comparison-
dc.titleDose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strainen_US
dc.typeArticleen_US
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_US
dc.identifier.emailTo, KKW: kelvinto@hkucc.hku.hken_US
dc.identifier.emailChan, KH: chankh2@hkucc.hku.hken_US
dc.identifier.emailZhang, AJ: zhangajx@hotmail.comen_US
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.authorityHung, IFN=rp00508en_US
dc.identifier.authorityTo, KKW=rp01384en_US
dc.identifier.authorityYuen, KY=rp00366en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2012.08.014-
dc.identifier.pmid22910287-
dc.identifier.scopuseid_2-s2.0-84866505857-
dc.identifier.hkuros210042en_US
dc.identifier.volume30-
dc.identifier.issue45-
dc.identifier.spage6427-
dc.identifier.epage6435-
dc.identifier.isiWOS:000310117200013-
dc.publisher.placeUnited Kingdom-
dc.identifier.citeulike11449073-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats